KRASG12D mutant cells are a type of genetically altered pancreatic cells that play a key role in pancreatic cancer development, specifically pancreatic ductal adenocarcinoma (PDAC). Normally, the pancreas has protective mechanisms to eliminate mutant cells to maintain healthy tissue and prevent cancer.
KRASG12D mutant cells are a type of genetically altered pancreatic cells that play a key role in pancreatic cancer development, specifically pancreatic ductal adenocarcinoma (PDAC). Normally, the pancreas has protective mechanisms to eliminate mutant cells to maintain healthy tissue and prevent cancer. However, KRASG12D mutant cells manage to bypass these natural elimination systems and persist in the pancreas.
The study found that Wnt5a signaling is crucial for helping KRASG12D mutant cells survive. Wnt5a is part of the noncanonical Wnt signaling pathway, which is different from the β-catenin-dependent pathway. In KRASG12D mutant cells, Wnt5a signaling stabilizes cell junctions by increasing E-cadherin and β-catenin levels, making the cells stick together more tightly. This prevents their expulsion from the pancreatic tissue. Additionally, Wnt5a suppresses E-cadherin internalization, reducing the cells' motility and anchoring them in place.
KRASG12D cells also enter a state of dormancy, where they stop dividing but remain alive. This dormancy is marked by high levels of proteins like p27 and Sox9, which protect the cells from immune clearance and apoptosis (cell death). Dormancy allows these mutant cells to survive long-term and gain stem-like properties, increasing their tumor-initiating potential.
When KRASG12D is combined with another mutation, p53R172H, the elimination of mutant cells is completely blocked, leading to preneoplastic lesions and tumors. Targeting Wnt5a signaling or reversing dormancy could potentially prevent these mutant cells from surviving and progressing into cancer, offering new therapeutic strategies for pancreatic cancer.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.